Amgen (AMGN) Free Cash Flow (2009 - 2026)
Amgen's quarterly Free Cash Flow came in at $1.5 billion in Q1 2026, up 50.71% year-on-year from $980.0 million in Q1 2025, and up 53.69% quarter-over-quarter from $961.0 million in Q4 2025.
Amgen has reported Free Cash Flow for 18 years, with the latest figure at $1.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 50.71% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $8.6 billion (down 21.24% YoY), and the FY2025 full-year result was $8.1 billion, down 22.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at $1.5 billion, up from $961.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $4.4 billion in Q4 2024, with the low at $289.0 million in Q4 2023.
- Average Free Cash Flow over 5 years is $2.1 billion, with a median of $2.0 billion recorded in 2022.
- Year-over-year, Free Cash Flow tumbled 87.48% in 2023 and soared 1422.49% in 2024.
- Tracing AMGN's Free Cash Flow over 5 years: stood at $2.3 billion in 2022, then plunged by 87.48% to $289.0 million in 2023, then soared by 1422.49% to $4.4 billion in 2024, then sank by 78.16% to $961.0 million in 2025, then jumped by 53.69% to $1.5 billion in 2026.
- The last three Free Cash Flow figures came in at $1.5 billion (Q1 2026), $961.0 million (Q4 2025), and $4.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Bn |
| Mar 31, 2026 | 1.48 Bn |
| Dec 31, 2025 | 961.00 Mn |
| Dec 31, 2025 | 961.00 Mn |
| Sep 30, 2025 | 4.25 Bn |
| Sep 30, 2025 | 4.25 Bn |
| Jun 30, 2025 | 1.91 Bn |
| Jun 30, 2025 | 1.91 Bn |
| Mar 31, 2025 | 980.00 Mn |
| Mar 31, 2025 | 980.00 Mn |
| Dec 31, 2024 | 4.40 Bn |
| Dec 31, 2024 | 4.40 Bn |
| Sep 30, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.31 Bn |
| Jun 30, 2024 | 2.22 Bn |
| Jun 30, 2024 | 2.22 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Mar 31, 2024 | 459.00 Mn |
| Dec 31, 2023 | 289.00 Mn |
| Dec 31, 2023 | 289.00 Mn |
| Sep 30, 2023 | 2.51 Bn |
| Sep 30, 2023 | 2.51 Bn |
| Jun 30, 2023 | 3.84 Bn |
| Jun 30, 2023 | 3.84 Bn |
| Mar 31, 2023 | 720.00 Mn |
| Mar 31, 2023 | 720.00 Mn |
| Dec 31, 2022 | 2.31 Bn |
| Dec 31, 2022 | 2.31 Bn |
| Sep 30, 2022 | 2.82 Bn |
| Sep 30, 2022 | 2.82 Bn |
| Jun 30, 2022 | 1.68 Bn |
| Jun 30, 2022 | 1.68 Bn |
| Mar 31, 2022 | 1.97 Bn |
| Mar 31, 2022 | 1.97 Bn |
| Dec 31, 2021 | 2.52 Bn |
| Dec 31, 2021 | 2.52 Bn |
| Sep 30, 2021 | 2.18 Bn |
| Sep 30, 2021 | 2.18 Bn |
| Jun 30, 2021 | 1.75 Bn |
| Jun 30, 2021 | 1.75 Bn |
| Mar 31, 2021 | 1.94 Bn |
| Mar 31, 2021 | 1.94 Bn |
| Dec 31, 2020 | 1.98 Bn |
| Dec 31, 2020 | 1.98 Bn |
| Sep 30, 2020 | 3.23 Bn |
| Sep 30, 2020 | 3.23 Bn |
| Jun 30, 2020 | 2.68 Bn |
| Jun 30, 2020 | 2.68 Bn |
| Mar 31, 2020 | 1.99 Bn |
| Mar 31, 2020 | 1.99 Bn |
| Dec 31, 2019 | 2.33 Bn |
| Dec 31, 2019 | 2.33 Bn |
| Sep 30, 2019 | 3.21 Bn |
| Sep 30, 2019 | 3.21 Bn |
| Jun 30, 2019 | 1.27 Bn |
| Jun 30, 2019 | 1.27 Bn |
| Mar 31, 2019 | 1.73 Bn |
| Mar 31, 2019 | 1.73 Bn |
| Dec 31, 2018 | 2.97 Bn |
| Dec 31, 2018 | 2.97 Bn |
| Sep 30, 2018 | 3.10 Bn |
| Sep 30, 2018 | 3.10 Bn |
| Jun 30, 2018 | 1.92 Bn |
| Jun 30, 2018 | 1.92 Bn |
| Mar 31, 2018 | 2.57 Bn |
| Mar 31, 2018 | 2.57 Bn |
| Dec 31, 2017 | 2.86 Bn |
| Dec 31, 2017 | 2.86 Bn |
| Sep 30, 2017 | 3.30 Bn |
| Sep 30, 2017 | 3.30 Bn |
| Jun 30, 2017 | 2.14 Bn |
| Jun 30, 2017 | 2.14 Bn |
| Mar 31, 2017 | 2.22 Bn |
| Mar 31, 2017 | 2.22 Bn |
| Dec 31, 2016 | 2.87 Bn |
| Dec 31, 2016 | 2.87 Bn |
| Sep 30, 2016 | 2.50 Bn |
| Sep 30, 2016 | 2.50 Bn |
| Jun 30, 2016 | 2.49 Bn |
| Jun 30, 2016 | 2.49 Bn |
| Mar 31, 2016 | 1.76 Bn |
| Mar 31, 2016 | 1.76 Bn |
| Dec 31, 2015 | 1.87 Bn |
| Dec 31, 2015 | 1.87 Bn |
| Sep 30, 2015 | 2.75 Bn |
| Sep 30, 2015 | 2.75 Bn |
| Jun 30, 2015 | 3.15 Bn |
| Jun 30, 2015 | 3.15 Bn |
| Mar 31, 2015 | 1.36 Bn |
| Mar 31, 2015 | 1.36 Bn |
| Dec 31, 2014 | 2.64 Bn |
| Dec 31, 2014 | 2.64 Bn |
| Sep 30, 2014 | 2.57 Bn |
| Sep 30, 2014 | 2.57 Bn |
| Jun 30, 2014 | 2.05 Bn |
| Jun 30, 2014 | 2.05 Bn |
| Mar 31, 2014 | 970.00 Mn |
| Mar 31, 2014 | 970.00 Mn |
| Dec 31, 2013 | 1.63 Bn |
| Dec 31, 2013 | 1.63 Bn |
| Sep 30, 2013 | 1.63 Bn |
| Sep 30, 2013 | 1.63 Bn |
| Jun 30, 2013 | 1.44 Bn |
| Jun 30, 2013 | 1.44 Bn |
| Mar 31, 2013 | 891.00 Mn |
| Mar 31, 2013 | 891.00 Mn |
| Dec 31, 2012 | 612.00 Mn |
| Dec 31, 2012 | 612.00 Mn |
| Sep 30, 2012 | 1.55 Bn |
| Sep 30, 2012 | 1.55 Bn |
| Jun 30, 2012 | 2.20 Bn |
| Jun 30, 2012 | 2.20 Bn |
| Mar 31, 2012 | 828.00 Mn |
| Mar 31, 2012 | 828.00 Mn |
| Dec 31, 2011 | 1.36 Bn |
| Dec 31, 2011 | 1.36 Bn |
| Sep 30, 2011 | 849.00 Mn |
| Sep 30, 2011 | 849.00 Mn |
| Jun 30, 2011 | 1.41 Bn |
| Jun 30, 2011 | 1.41 Bn |
| Mar 31, 2011 | 930.00 Mn |
| Mar 31, 2011 | 930.00 Mn |
| Dec 31, 2010 | 1.83 Bn |
| Dec 31, 2010 | 1.83 Bn |
| Sep 30, 2010 | 1.18 Bn |
| Sep 30, 2010 | 1.18 Bn |
| Jun 30, 2010 | 1.39 Bn |
| Jun 30, 2010 | 1.39 Bn |
| Mar 31, 2010 | 819.00 Mn |
| Mar 31, 2010 | 819.00 Mn |
| Dec 31, 2009 | 1.68 Bn |
| Dec 31, 2009 | 1.68 Bn |
| Sep 30, 2009 | 1.85 Bn |
| Sep 30, 2009 | 1.85 Bn |
| Jun 30, 2009 | 1.54 Bn |
| Jun 30, 2009 | 1.54 Bn |
| Mar 31, 2009 | 742.00 Mn |
| Mar 31, 2009 | 742.00 Mn |